To date, ALK mutations and MYCN amplification are the only validated de novo drivers of neuroblastoma [22,23], although a number of other commonly over-expressed proteins and low frequency somatic mutations have been implicated in tumour progression and drug resistance. Here, ALK is linked to neoplasm.